Health
Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan
CAMBRIDGE, Mass., February 24, 2026--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced the commercial launch of ELEVIDYS (delandistrogene moxeparvovec) in Japan by Chugai Pharmaceutical Co., Ltd., following its reimbursement listing on Japan’s National Health Insurance (NHI) price list.
About this update from Chugai Pharmaceutical Co., Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":426,"url":"https://media.zenfs.com/en/business-wire.com/5622886761066f7ab407feff764eab06"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/zF4y03QKFm0ZAEoCgvO9oA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTg1MjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/5622886761066f7ab407feff764eab06","width":480,"height":426}},"lazy":false},{"type":"text","content":"- Japan now offers ELEVIDYS gene therapy to children with Duchenne muscular dystrophy aged 3 years to less than 8 years","length":119,"tagName":"p"},{"type":"text","content":"- Company is eligible to receive a $40 million milestone payment upon first commercial sale in Japan","length":100,"tagName":"p"},{"type":"text","content":"CAMBRIDGE, Mass., February 24, 2026--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced the commercial launch of ELEVIDYS (delandistrogene moxeparvovec) in Japan by Chugai Pharmaceutical Co., Ltd., following its reimbursement listing on Japan’s National Health Insurance (NHI) price list.","length":366,"tagName":"p"},{"type":"text","content":"Elevidys is the first gene therapy to be launched in Japan for Duchenne muscular dystrophy (DMD). In Japan, ELEVIDYS is available for ambulatory individuals with Duchenne ages 3-to less than 8-years-old, a deletion of any portion or the entirety of exon 8 and/or exon 9 in the DMD gene, and who are negative for anti-AAVrh74 antibodies.","length":336,"tagName":"p"},{"type":"text","content":""The commercial launch of ELEVIDYS in Japan marks an important step in expanding access to this therapy, where early intervention may offer the greatest opportunity to preserve muscle function," said Louise Rodino-Klapac‑, Ph.D., president of research & development and technical operations, Sarepta. "We are delighted that ELEVIDYS is now available to eligible patients in Japan and remain focused on advancing rigorous science and generating long-term clinical and real-world evidence to help inform care for the Duchenne community worldwide."","length":569,"tagName":"p"},{"type":"text","content":"Chugai announced that ELEVIDYS has been launched in Japan following reimbursement listing, ena...